The Johnson & Johnson spinoff that sells Tylenol is defending the medicine's safety profile as it comes under attack from the Trump administration.
Why it matters: The over-the-counter drug is a critical product for Kenvue, anchoring the company's "self-care" segment, which brings in about 42% of its total revenue.
